MAXCYTE, INC. Logo

MAXCYTE, INC.

Provides a scalable, non-viral electroporation platform for cell therapy development.

MXCT | US

Overview

Corporate Details

ISIN(s):
US57777K1060 (+2 more)
LEI:
54930053YHXULRFCU991
Country:
United States of America
Address:
9713 KEY WEST AVENUE,, 20850 ROCKVILLE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MaxCyte, Inc. is a commercial-stage cell-engineering company providing enabling platform technologies for the discovery, development, and commercialization of cell-based therapeutics. The company's core offering is its proprietary, non-viral Flow Electroporation® technology, delivered through the scalable ExPERT™ platform. This system facilitates high-efficiency engineering of complex cell types for a wide range of applications, including cell therapy, protein production, cell-based assays, and gene editing. In addition to its technology platform, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate gene editing safety. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-26 11:14
Director's Dealing
Correction: Vesting of RSUs and PDMR Dealing
English 57.0 KB
2025-03-26 08:00
Director's Dealing
Vesting of RSUs and PDMR Dealing
English 55.7 KB
2025-03-25 11:30
Major Shareholding Notification
Holding(s) in Company
English 88.0 KB
2025-03-25 11:28
Major Shareholding Notification
Holding(s) in Company
English 87.7 KB
2025-03-25 11:26
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB
2025-03-25 11:22
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB

Automate Your Workflow. Get a real-time feed of all MAXCYTE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MAXCYTE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MAXCYTE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Hoth Therapeutics, Inc. Logo
Advancing therapeutics for metabolic, dermatologic, and inflammatory diseases.
United States of America
HOTH
Human Stem Cells Institute PJSC Logo
A biotech investor developing gene therapy, regenerative medicine, and genetic services.
Russian Federation
ISKJ
HVIVO PLC Logo
A CRO running human challenge trials to test infectious disease vaccines for pharma/biotech clients.
United Kingdom
HVO
Hybrigenics SA Logo
R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.
France
ALHYG
Korean CRO offering end-to-end clinical trial services for pharma & bio ventures.
South Korea
187660
HYUNDAI BIOSCIENCE CO., LTD. Logo
Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.
South Korea
048410
ICON PLC Logo
Global CRO providing outsourced development & commercialization for pharma, biotech & device firms.
United States of America
ICLR
IGC Pharma, Inc. Logo
Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.
United States of America
IGC
IMCB PJSC Logo
Personal biobank preserving umbilical cord stem cells for families' future therapeutic use.
Russian Federation
GEMA
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.